PLASMA PHOSPHOLIPID TRANSFER PROTEIN (PLTP) DEFICIENCY REPRESENTS AN ANTI-ATHEROGENIC STATE AND PLTP INHIBITOR HAS ANTI-ATHEROSCLEROSIS ACTION

Title:

PLASMA PHOSPHOLIPID TRANSFER PROTEIN (PLTP) DEFICIENCY REPRESENTS AN ANTI-ATHEROGENIC STATE AND PLTP INHIBITOR HAS ANTI-ATHEROSCLEROSIS ACTION

Document Type and Number:

WIPO Patent Application WO2002068450

Kind Code:

A3

Abstract:

This invention provides methods of decreasing apolipoprotein and of treating atherosclerotic diseases and dyslipidemic diseases by reducing plasma phospholipid transfer protein activity, and methods of identifying chemical compounds for use in such treatments. Figure (1) shows plasma lipoprotein analysis by fast protein liquid chromatography and SDS-PAGE analysis of apoB from ultracentrifugally isolated plasma lipoproteins.

More Like This:

WO2001009325	HUMAN P53 MUTATIONS AND A GENETIC SYSTEM IN YEAST FOR FUNCTIONAL INDENTIFICATION OF HUMAN P53 MUTATIONS
JP2010521425	Improvement of cell stress response
JP2006518605	Diagnosis based on microarray of pediatric hearing impairment and construction of deafness gene chip

Inventors:

JIANG XIAN-CHENG
TALL ALAN R

Application Number:

PCT/US2002/005694

Publication Date:

April 10, 2003

Filing Date:

February 22, 2002

Export Citation:

Click for automatic bibliography generation Help

Assignee:

UNIV COLUMBIA (US)

International Classes:

G01N33/50; G01N33/68; G01N33/92; (IPC1-7): C12Q1/48; A01N43/42; C12Q1/00; C12Q1/37

Foreign References:

US5919795A	1999-07-06
US5610019A	1997-03-11

Download PDF:

View/Download PDF PDF Help

Previous Patent: METHOD FOR EVALUATING THE ABILITY TO METABOLIZE PHARMACEUTICALS AND COMPOSITIONS THEREFOR

Next Patent: SPERM PROTEIN 17 FOR THE DIAGNOSIS AND TREATMENT OF CANCER